Fiztasovimab
Fiztasovimab (NPC-21; EV2038) is a fully human IgG1λ mAb against human cytomegalovirus (hCMV) . Fiztasovimab acts neutralizing activity by binding to the antigenic domain 1 of glycoprotein B on hCMV envelope. Fiztasovimab inhibits cell-to-cell transmission of hCMV[1].
Product Specifications
CAS Number
[2467411-25-0]
Product Name Alternative
NPC-21; EV2038
UNSPSC
12352203
Target
CMV
Type
Inhibitory Antibodies
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/fiztasovimab.html
Purity
96.49
Solubility
10 mM in DMSO
Smiles
[Fiztasovimab]
Molecular Weight
(144.49 kDa)
References & Citations
[1]Furihata K, et al. Pharmacokinetics, Safety, and Tolerability of NPC-21, an Anti-Cytomegalovirus Monoclonal Antibody, in Healthy Japanese and White Adult Men: A Randomized, Placebo-Controlled, First-in-Human Phase 1 Study. Clin Pharmacol Drug Dev. 2022 Jun;11 (6) :707-716.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS6253516-01 0.1 mL
CD274 (CD274 Antigen, B7 Homolog 1, B7H1, B7-H1, B7-H, MGC142294, MGC142296, OTTHUMP00000021029, Programmed Cell Death 1 Ligand 1, PDCD1 Ligand 1, PDCD1L1, PDCD1LG1, Programmed Death Ligand 1, PDL1, PD-L1, RGD1566211) (MaxLight 490)
Sign In for Pricing
View Details